Table 2. Selected ongoing phase III trials in metastatic castrate-resistant prostate cancer (source: http://www.clinicaltrials.gov).
| Trial | Disease state | Trial arms | Estimated completion date | Primary outcome |
|---|---|---|---|---|
| PREVAIL | First-line, asymptomatic | Enzalutamide vs. placebo | Sep 2014 | OS, PFS |
| PROSPECT | First-line, asymptomatic | PROSTVAC+GM-CSF vs. PROSTVAC+GM-CSF placebo vs. placebo | Aug 2015 | OS |
| CA-184-095 | First-line, asymptomatic | Ipilimumab vs. placebo | Jan 2016 | OS |
| NCT0123431 | First-line, asymptomatic | Tasquimod vs. placebo | Jan 2016 | OS |
| FIRSTANA | First-line | Cabazitaxel+prednisone vs. DP | Dec 2017 | OS |
| C21004 | First-line | Ortonel+prednisone vs. prednisone | Jun 2014 | rPFS, OS |
| SYNERGY | First-line | DP vs. DP+custirsen | Dec 2013 | OS |
| READY | First-line | dasatinib+docetaxel+prednisone vs. docetaxel+prednisone | Feb 2013 | OS |
| PROSELICA | Second-line | Cabazitaxel+prednisone at 20 mg m−2 vs. 25 mg m−2 | Sep 2017 | OS |
| CA-184-043 | Second-line | Ipilimumab vs. placebo | Sep 2013 | OS |
| C21005 | Second-line | Ortonel+prednisons vs. prednisone | Oct 2013 | OS |
| AFFINITY | Second-line | Cabazitazel+prednisone+custirsen vs. cabazitazel+prednisone | Dec 2015 | OS |
| COMET-1 | Third-line | Cabozantinib vs. prednisone | Mar 2014 | OS |
Abbreviations: DP, doxetaxol+prednisone; GM-CSF, granulocyte-macrophage colony-stimulating factor; OS, overall survival; PFS, progression-free survival; rPFS, radiographic progression-free survival.